New Zealand Shares Rebound Despite Retail Sales Slide; Fisher & Paykel Healthcare Surges 10% on Upgraded Outlook

MT Newswires Live08-23

New Zealand shares ended the week on a positive note as shares rebounded on Friday despite a decline in retail sales for the June quarter.

The NS&P/NZX 50 Index rose 0.49% or 60.64 points to close at 12,529.99.

Government agency Stats NZ reported that New Zealand's seasonally adjusted retail sales volume declined 1.2% to NZ$24.5 billion in the three months ended June compared with the previous quarter. This followed a 0.4% increase in the March quarter.

The decline was less severe than analysts had anticipated, as reported by interest.co.nz, which helped to buoy market sentiment despite the dip.

In a separate report, Stats NZ said regional greenhouse gas emissions in New Zealand declined by 1.8%, or 1,440 kilotonnes, to 76,809 kilotonnes of carbon dioxide equivalents between 2022 and 2023.

In corporate news, shares of Fisher & Paykel Healthcare (NZE:FPH, ASX:FPH, which manufactures respiratory care, sleep apnea, and surgery products, rose 10% at market close after upgrading its guidance for the fiscal year 2025. The company expects expects operating revenue of NZ$1.9 billion to NZ$2 billion and net profit after tax of NZ$320 million to NZ$370 million.

Elsewhere, New Zealand's Commerce Commission found that Fletcher Building (NZE:FBU, ASX:FBU) subsidiary Winstone Wallboards breached the Commerce Act after an investigation into Winstone Wallboards' use of volume rebates. Shares of the building materials firm declined 9% at market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment